
Medeze Group launches partial offer for 10% stake in Cordlife
The offer is priced at $0.25 per share.
Thailand-listed Medeze Group Public Company Limited has announced a voluntary conditional cash partial offer to acquire 10% of Cordlife Group Limited.
The offer, made through Medeze’s wholly owned subsidiary, Medeze Treasury Pte. Ltd., is priced at $0.25 per share — a 61.3% premium over Cordlife’s last traded price of $0.155 on 9 May 2025.
The offeror aims to purchase 25,630,774 shares, subject to a minimum acceptance condition that this full amount is tendered. The offer will not proceed unless this condition is met.
This is Medeze’s first move into the Singapore market and is intended to open doors for business collaboration with Cordlife. If successful, Medeze’s stake in Cordlife will increase to 10.68%.
Medeze plans to work with Cordlife’s existing management and shareholders to explore long-term strategic partnerships. Potential collaboration areas include offering Medeze’s NK cell and hair follicle banking services to Cordlife customers, while Cordlife could provide genetic screening services to Medeze clients.
Medeze reported strong financial results in its latest fiscal year, with revenue of $34.15 m (THB 874.3m) and net profit of $13.22m (THB 338.7m). Its total assets now exceed $132.78 m (THB 3.4b), boosted by its recent listing on the Stock Exchange of Thailand and investments in tech and capacity.